AirSculpt Technologies Bolsa (NASDAQ: AIRS)

Últimas noticias sobre AirSculpt Technologies (NASDAQ:AIRS) Bolsa

AirSculpt Technologies

AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies Inc

AirSwap - United States Dollar

Airship AI Holdings, Inc - Class A Common Stock

Airship AI Holdings Inc

Airspan Networks Holdings Inc

Airspan Networks Holdings Inc Warrants (01/11/2026)

Airspan Networks Holdings Inc Warrants - Class C (01/11/2026)

Traders adopted a cautious approach on Monday as they awaited two critical inflation reports due later this week, seeking clarity on Federal <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42953940/tuesdays-producer-inflation-report-could-stoke-market-volatility-as-fed-path-remains-unclear">Reserve interest rate policy. </a>
Additionally, the kickoff of earnings season, led by major banks on Wednesday, added to <a href="https://www.benzinga.com/markets">the market&#8217;s subdued tone.</a>
The S&amp;P 500 and Nasdaq 100 edged lower, continuing Friday&#8217;s downturn sparked by unexpectedly strong jobs data. The lack of &#8220;buy-the-dip&#8221; enthusiasm in the tech-heavy indices signaled lingering uncertainty among investors.
In contrast, the Dow Jones Industrial Average eked out a gain, buoyed by a rally in energy stocks. Rising oil prices provided a key lift, as West Texas Intermediate (WTI) crude oil surged over 3% to approach $78 per barrel — a level last seen in mid-August 2024. The spike followed U.S. sanctions on Russian crude exports announced on Friday, which shifted market expectations around supply and demand.
Treasury yields extended their ascent, with the 10-year yield climbing to 4.79% and the 30-year yield rising to 4.97%, reflecting heightened expectations for tighter monetary policy. Bank of America Securities launched a bombshell indicating rising risks towards a rate hike as the next Fed move.
Commodity markets saw mixed action. Gold endured its sharpest daily loss in nearly a month, falling more than 1% as rising yields weighed on the precious metal. Meanwhile, copper staged a modest rebound, gaining 0.8% after a 0.5% decline last Friday.
Cryptocurrencies faced renewed volatility, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) plunging 3% to dip below $92,000, briefly touching a two-month low. The ripple effects extended to crypto-linked equities: MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) slid more than 3%, while Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) dropped nearly 4%.
<h1 class="wp-block-heading">Monday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day chg. %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,144.04</td>
<td>0.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,822.92</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,183.39</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,739.92</td>
<td>-0.5%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.1% lower to $579.98.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.7% to $422.03.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.6% to $504.44.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) dipped 0.3% to $216.19.</li>
<li>The&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 2.3%; the&nbsp;Technology Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) lagged, down 1.1%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
<ul>
<li>Major oil &amp; gas giants rallying on Monday include Valero Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>), up 5%, Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) up 3.9%, and Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) up 3.5%.</li>
<li>Health insurance companies surged after a government proposal suggested increased payments for Medicare Advantage plans in 2026, lifting sentiment across the sector.</li>
<li>Shares of Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) rose 7.8%, CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) followed closely with a 6.9% jump, while UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) saw a 4.8% increase.+</li>
<li>NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) dropped 2.7% to $132.19 as the AI chipmaker urged President-elect Donald Trump to oppose Biden administration regulations on AI technology. Meanwhile, HSBC cut its price target from $195 to $185 but reaffirmed its Buy rating.</li>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) plummeted 20% after projecting 2025 revenue of $1.5 billion to $2.5 billion, missing analysts&#8217; estimates of $2.92 billion. The company also announced it would fast-track its cost-cutting measures.</li>
<li>Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) fell 12% as authorities investigated whether equipment from its subsidiary, Southern California Edison, played a role in sparking the Hurst fire in Los Angeles.</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42948649/goldman-sachs-warns-of-90-oil-risk-trump-may-not-ease-sanctions-once-he-takes-office">Oil Could Hit $90, Goldman Sachs Says: &#8216;Trump May Not Ease Sanctions&#8217; On Russia</a></li>
</ul>
Photo: Ryan DeBerardinis via Shutterstock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

ETFs

$BTC

COIN

SPDR Dow Jones Industrial Average ETF Trust

MRNA

MSTR

NVDA

Stocks Edge Down Ahead Of Key Inflation Reports, Crude Hits 5-Month High, Bitcoin Sinks: What's Driving Markets Monday?

DatChat Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>) shares climbed 13.9% to $5.50 on Monday, recovering some losses after <a href="https://www.benzinga.com/news/25/01/42877960/why-datchat-dats-stock-is-getting-hammered">last week's pullback</a>. Monday&#8217;s rally occurred despite no new company-specific updates.
What To Know: Last Wednesday, DatChat shares plunged 64% to $3.22 after announcing a <a href="https://www.benzinga.com/pressreleases/25/01/g42873083/datchat-inc-announces-pricing-of-5-1-million-registered-direct-offering-priced-at-the-market-under">$5.1 million registered direct offering</a> priced at-the-market under Nasdaq rules. 
The company said plans to sell 1.2 million shares at $4.25 per share, with Benchmark Company, LLC acting as the sole placement agent. The offering aims to fund working capital and general corporate purposes.
Investors reacted sharply to the announcement, concerned about potential dilution. Monday's surge reflects renewed interest possibly driven by speculative activity.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42953757/whats-going-on-with-trump-media-technology-group-stock-4">What&#8217;s Going On With Trump Media &amp; Technology Group Stock?</a>
<h2 class="wp-block-heading">How To Buy DATS Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in DatChat&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, DATS has a 52-week high of $9.34 and a 52-week low of $1.01.

News

DATS

DatChat (DATS) Stock Jumps After Last Week's Plunge: What's Going On?

UBS analyst Ashwani Verma maintains Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) with a Buy and lowers the price target from $22 to $14.

Price Target

Analyst Ratings

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

UBS Maintains Buy on Avadel Pharmaceuticals, Lowers Price Target to $14

CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Humana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) and UnitedHealth Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) stock is moving higher on Monday. Here&#8217;s what you <a href="https://www.benzinga.com//node/42953047">need to know</a>.
What To Know: Shares of health insurance companies are trading higher after The Centers for Medicare and Medicaid Services proposed a rise to Medicare Advantage payments.
According to <a href="https://www.bloomberg.com/news/articles/2025-01-10/us-proposes-21-billion-boost-to-insurers-for-medicare-payments?embedded-checkout=true">Bloomberg</a>, the proposal suggests an average 4.3% increase in Medicare Advantage plan payments. If the plan is adopted, it could lead to an additional $21 billion in payments for 2026 compared to the expected 2025 figures.
This follows concerns from health insurers that current rates are too low to cover medical expenses. 
"While rates in recent years have been considered insufficient" by Medicare insurers, "there is some optimism that rates could improve under a Trump CMS," said JPMorgan analyst Lisa Gill told Bloomberg.
Health insurance companies offering Medicare Advantage plans receive direct payments from the federal government to cover beneficiaries. An increase in these payments could drive higher revenue and improved margins, likely boosting investor confidence in these companies.
Notably, CVS, Humana and UnitedHealth sold more than half of the Medicare Advantage plans in 2024, as reported by KFF. Additionally, the Medicare Payment Advisory Commission noted that Medicare Advantage covered more than half of Medicare beneficiaries in 2023.
The U.S. is expected to spend $9.2 trillion over the next decade on payments to private Medicare plans.
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42953757/whats-going-on-with-trump-media-technology-group-stock-4">What&#8217;s Going On With Trump Media &amp; Technology Group Stock?</a>
Price Action: At the time of publication, CVS stock is trading 7.43% higher at $51.56, Humana shares are trading 7.38% higher at $289.98 and UnitedHealth stock is moving 4.37% higher at $543.48, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

Movers

What's Going On With CVS, Humana and UnitedHealth Shares Monday?

Instacart parent company Maplebear Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) received an upgrade to Buy while also getting added to Needham&#8217;s conviction list on Monday as analysts expressed <a href="https://www.benzinga.com/25/01/42880309/instacart-grows-stronger-sp-midcap-400-inclusion-and-ulta-partnership-boosts-stock">concern over increasing competition</a>.
What Happened: Needham analyst Bernie McTernan upgraded Maplebear from a <a href="https://www.benzinga.com/analyst-stock-ratings">Hold rating</a> to a Buy rating. He also set a price target of $56, suggesting a nearly 30% upside from current levels.
&#8220;We think the stronger than expected results in &#8217;24E suggest our fears over competition and TAM pull forward are overblown likely driven by CART&#8217;s leading customer experience in grocery, which they continue to improve,&#8221; the Needham analyst said in a new note to clients.
Maplebear last reported quarterly earnings in November, turning in its fourth straight quarter of positive GAAP net income. Revenue jumped 12% year-over-year as orders jumped 10%. The San Francisco-based company guided for continued growth between 8% and 10%.
Check This Out: <a href="https://www.benzinga.com/news/retail-sales/25/01/42952591/thc-infused-drinks-gummies-candy-via-doordash">THC-Infused Drinks, Gummies, Candy Coming Soon To Your Front Porch Via DoorDash</a>
The Needham analyst believes Maplebear&#8217;s <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/news/earnings/24/11/41938001/why-is-instacart-parent-maplebear-stock-sliding-today&amp;ved=2ahUKEwi7uMSxr_OKAxVD8MkDHawDPFsQFnoECBoQAQ&amp;usg=AOvVaw0w8E5Rohhvl2okt8D4GZhH">recent results</a> show stronger-than-expected customer behavior. This creates the potential for double-digit growth in the firm&#8217;s bull case. Needham put a bull case price target of $80 on Maplebear shares.
&#8220;Growth expectations for &#8217;24 have been on the rise during the second half of the year, providing further evidence to us that COVID cohorts are stable and post-COVID cohorts are large enough to drive consolidated GTV growth,&#8221; the analyst said.
McTernan noted that there&#8217;s a lot of competition in the grocery delivery space.
Maplebear stands out among consumers given its leading customer experience, McTernan says. His grocery tracking research suggests that the company maintains its supply lead versus competitors like DoorDash Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) and Uber Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>).
Investors have some downside protection because of potential M&amp;A opportunities in the space. Uber is looking to diversify revenue streams away from mobility. Therefore, Maplebear could be an enticing acquisition, McTernan says.
&#8220;However, given the recent price movements, we think the math is difficult to get to work, which is why we view M&amp;A as floor support,&#8221; the analyst said.
&#8220;While we are not the first to write about the potential for M&amp;A between Uber and [Instacart], we do see the structural logic, and it makes more sense now if Uber mobility fears are founded on autonomous vehicles,&#8221; he added.
Price Action: <a href="http://benzinga.com/quote/cart">Maplebear shares</a> are up approximately 90% over the past year. The stock was down 0.43% at $44.04 at the time of writing Monday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42954168/investors-bet-big-on-alphabet-uber-genai-in-2025-what-jpmorgan-survey-reveals">Investors Bet Big On Alphabet, Uber, GenAI In 2025: What JPMorgan Survey Reveals</a></li>
</ul>
Photo: Shutterstock

Upgrades

CART

DASH

UBER

Instacart, Uber Deal 'Makes More Sense Now,' Analyst Says: Here's Why

Whales with a lot of money to spend have taken a noticeably bearish stance on GameStop.
Looking at options history for GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) we detected 33 trades.
If we consider the specifics of each trade, it is accurate to state that 27% of the investors opened trades with bullish expectations and 60% with bearish.
From the overall spotted trades, 20 are puts, for a total amount of $1,020,111 and 13, calls, for a total amount of $550,005.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.0 to $125.0 for GameStop over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for GameStop's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of GameStop's whale trades within a strike price range from $22.0 to $125.0 in the last 30 days. 
<h3>GameStop 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736795730_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GME</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$10.3</td>
<td>$10.1</td>
<td>$10.1</td>
<td>$22.00</td>
<td>$101.0K</td>
<td>49</td>
<td align="right">0</td>
</tr>
<tr>
<td>GME</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$6.45</td>
<td>$5.9</td>
<td>$6.2</td>
<td>$27.00</td>
<td>$62.0K</td>
<td>809</td>
<td align="right">101</td>
</tr>
<tr>
<td>GME</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$95.75</td>
<td>$95.6</td>
<td>$95.75</td>
<td>$125.00</td>
<td>$57.4K</td>
<td>5.9K</td>
<td align="right">34</td>
</tr>
<tr>
<td>GME</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$95.65</td>
<td>$95.65</td>
<td>$95.65</td>
<td>$125.00</td>
<td>$57.3K</td>
<td>5.9K</td>
<td align="right">118</td>
</tr>
<tr>
<td>GME</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$95.6</td>
<td>$93.1</td>
<td>$95.6</td>
<td>$125.00</td>
<td>$57.3K</td>
<td>5.9K</td>
<td align="right">70</td>
</tr>
</tbody>
</table>

<h3>About GameStop</h3>
GameStop Corp is a U.S. multichannel video game, consumer electronics, and services retailer. The company operates across Europe, Canada, Australia, and the United States. GameStop sells new and second-hand video game hardware, physical and digital video game software, and video game accessories, mainly through GameStop, EB Games, and Micromania stores and international e-commerce sites. The majority of sales are from the United States.
In light of the recent options history for GameStop, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of GameStop</h3>
<ul>
<li>With a trading volume of 4,043,916, the price of GME is down by -2.51%, reaching $31.5.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 71 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for GameStop with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Spotlight on GameStop: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bearish approach towards Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ETN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Eaton Corp. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 38% leaning bullish and 46% bearish. Among these notable options, 5 are puts, totaling $183,484, and 8 are calls, amounting to $291,011.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $165.0 to $410.0 for Eaton Corp over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eaton Corp's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eaton Corp's whale trades within a strike price range from $165.0 to $410.0 in the last 30 days. 
<h3>Eaton Corp Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736795725_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$13.7</td>
<td>$13.1</td>
<td>$13.2</td>
<td>$340.00</td>
<td>$54.1K</td>
<td align="right">118</td>
<td align="right">148</td>
</tr>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$177.0</td>
<td>$173.4</td>
<td>$175.17</td>
<td>$165.00</td>
<td>$52.5K</td>
<td align="right">32</td>
<td align="right">3</td>
</tr>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$174.9</td>
<td>$170.7</td>
<td>$172.92</td>
<td>$170.00</td>
<td>$51.8K</td>
<td align="right">850</td>
<td align="right">3</td>
</tr>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$103.0</td>
<td>$99.0</td>
<td>$101.4</td>
<td>$250.00</td>
<td>$50.7K</td>
<td align="right">200</td>
<td align="right">5</td>
</tr>
<tr>
<td>ETN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$13.6</td>
<td>$13.1</td>
<td>$13.2</td>
<td>$340.00</td>
<td>$46.2K</td>
<td align="right">118</td>
<td align="right">106</td>
</tr>
</tbody>
</table>

<h3>About Eaton Corp</h3>
Founded in 1911 by Joseph Eaton, the eponymous company began by selling truck axles in New Jersey. Eaton has since become an industrial powerhouse largely through acquisitions in various end markets. Eaton's portfolio can broadly be divided into two parts: its electrical and industrial businesses. Its electrical portfolio (representing around 70% of company revenue) sells components within data centers, utilities, and commercial and residential buildings, while its industrial business (30% of revenue) sells components within commercial and passenger vehicles and aircraft. Eaton receives favorable tax treatment as a domiciliary of Ireland, but it generates over half of its revenue within the US.
In light of the recent options history for Eaton Corp, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Eaton Corp</h3>
<ul>
<li>Trading volume stands at 1,545,764, with ETN's price down by -0.51%, positioned at $339.71.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 17 days.</li>
</ul>
<h3>What The Experts Say On Eaton Corp</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $384.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Eaton Corp, maintaining a target price of $392. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Eaton Corp, which currently sits at a price target of $410. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Eaton Corp, which currently sits at a price target of $350. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eaton Corp options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Unpacking the Latest Options Trading Trends in Eaton Corp

Deep-pocketed investors have adopted a bullish approach towards JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in JD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 23 extraordinary options activities for JD.com. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 47% leaning bullish and 43% bearish. Among these notable options, 15 are puts, totaling $1,090,898, and 8 are calls, amounting to $751,010.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $25.0 and $60.0 for JD.com, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in JD.com's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to JD.com's substantial trades, within a strike price spectrum from $25.0 to $60.0 over the preceding 30 days.
<h3>JD.com Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736795720_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$2.2</td>
<td>$2.16</td>
<td>$2.16</td>
<td>$33.00</td>
<td>$432.0K</td>
<td>1.1K</td>
<td>2.0K</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$3.15</td>
<td>$3.0</td>
<td>$3.04</td>
<td>$30.00</td>
<td>$191.5K</td>
<td>1.1K</td>
<td>630</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.0</td>
<td>$13.75</td>
<td>$13.8</td>
<td>$45.00</td>
<td>$110.4K</td>
<td>1.6K</td>
<td>105</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.9</td>
<td>$4.65</td>
<td>$4.8</td>
<td>$37.50</td>
<td>$96.0K</td>
<td>3.6K</td>
<td>200</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$15.2</td>
<td>$14.95</td>
<td>$15.0</td>
<td>$47.50</td>
<td>$90.0K</td>
<td>331</td>
<td>180</td>
</tr>
</tbody>
</table>

<h3>About JD.com</h3>
JD.com is a leading e-commerce platform with its 2022 China GMV being similar to Pinduoduo (GMV not reported), on our estimate, but still lower than Alibaba. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
<h3>JD.com's Current Market Status</h3>
<ul>
<li>With a trading volume of 5,233,309, the price of JD is up by 1.39%, reaching $33.56.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 51 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for JD.com with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on JD.com Options

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 150 points on Monday.
The Dow traded up 0.64% to 42,206.46 while the NASDAQ dipped 0.79% to 19,010.47. The S&amp;P 500 also fell, dropping, 0.11% to 5,820.34.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/01/42944267/how-to-earn-500-a-month-from-fastenal-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Fastenal Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Energy shares rose by 1.6% on Monday.
In trading on Monday, utilities shares tumbled by 1.8%.
Top Headline
U.S. consumer inflation expectations for the year ahead came in unchanged at 3% in December, the same as in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares shot up 426% to $6.43 after the company reported promising results of second cohort from its ongoing clinical study of PH-762.</li>
<li>Shares of Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>)got a boost, surging 159% to $4.04. Salarius Pharmaceuticals and Decoy Therapeutics announced a definitive merger agreement.</li>
<li>Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) shares were also up, gaining 34% to $127.42 after Johnson &amp; Johnson agreed to acquire the company for $132.00 per share in cash for a total equity value of approximately $14.6 billion.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares dropped 20% to $33.67 after the company updated its 2025 expected revenue range to $1.5 billion to $2.5 billion, below analyst estimates of $2.951 billion.</li>
<li>Shares of Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) were down 18% to $132.09 after issuing mixed fourth-quarter and FY24 guidance.</li>
<li>Comtech Telecommunications Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) was down, falling 48% to $2.15 after the company announced downbeat quarterly results.</li>
</ul>
Commodities In commodity news, oil traded up 2.7% to $78.66 while gold traded down 1.4% at $2,677.60.
Silver traded down 3.1% to $30.345 on Monday, while copper rose 0.4% to $4.3195.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 declined 0.55%, Germany's DAX 40 fell 0.41% and France's CAC 40 dipped 0.30%. Spain's IBEX 35 Index fell 0.28%, while London's FTSE 100 slipped 0.29%.
Asia Pacific Markets
Asian markets closed lower on Monday, with China's Shanghai Composite Index falling 0.25%, Hong Kong's Hang Seng Index declining 1% and India's BSE Sensex falling 1.36%.
Economics
U.S. consumer inflation expectations for the year ahead came in unchanged at 3% in December, the same as in the previous month.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42947348/tesla-to-rally-around-9-here-are-10-top-analyst-forecasts-for-monday">Tesla To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Monday</a></li>
</ul>

Earnings

Equities

Eurozone

Intraday Update

Trading Ideas

CMTL

ITCI

PHIO

SLRX

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

-Reuters, citing source to Egypt's Al Qahera News&nbsp;

Rounds Of Intensive Talks Planned In Cairo To Put Final Touches On Remaining Details For Gaza Ceasefire Deal

A TikTok ban in the United States is approaching, as the Supreme Court signals support for enforcing a<a href="https://www.benzinga.com/24/12/42495579/lawmakers-demand-apple-and-google-remove-tiktok-by-jan-19-what-you-need-to-know"> Jan. 19 deadline.</a>
Here's a look at what happens to your app if the ban goes through, what could happen next, and what companies stand to benefit.
TikTok Ban Nears: The Supreme Court recently<a href="https://www.benzinga.com/25/01/42919029/supreme-court-hears-tiktok-oral-arguments"> heard oral arguments </a>from TikTok and parent company ByteDance ahead of a pending Jan. 19 ban. Based on the initial arguments, the ban seems likely to go through.
If the TikTok ban is upheld, Jan. 19 would mark the date that ByteDance would need to sell off the U.S. division of the company or face a ban of the app on app stores from Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>).
The ban would mean people who don't have the app already downloaded, like an estimated 170 million Americans, wouldn't be able to download it. 
For those who do have the TikTok app, the usability would quickly change. There would be no support for the app, no updates and the For You page could quickly go silent.
While this means that people would still be able to use TikTok, the lack of ability by ByteDance to push through any security updates and features could quickly make the app a risk to users with people targeting any vulnerabilities they can find that can't be remedied for users like other apps that can be updated.
ByteDance could opt to block access to TikTok in the U.S., a move that, while costly in terms of users and revenue, could increase pressure to overturn the ban or raise the valuation of a potential sale of its U.S. division, as existing users might become more vocal.
The U.S. government could also try to stop access to TikTok by having American internet service providers block the app.
If the ban is enforced, a potential trend to watch could be users listing phones with TikTok pre-installed for sale on auction platforms like eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>).
In 2020, some owners of iPhones with the mobile game "Fortnite" downloaded on them listed their phones for sale on eBay, as reported by PCMag. The move came after "Fortnite" owner Epic Games decided to skirt Apple's 30% cut of payments by offering a direct payment option. Apple removed the game from its app store, which kicked off a lengthy battle <a href="https://www.benzinga.com/news/21/05/20947603/epic-games-vs-apple-lawsuit-reveals-just-how-much-money-fortnite-has-made">between the two companies.</a>
Users also tried to sell their phones with mobile game "Flappy Bird" for high amounts of money back in 2014, as reported by <a href="https://www.pcmag.com/news/flappy-bird-equipped-iphones-selling-for-100k-on-ebay">PCMag</a>. The creator of the hit game pulled it from app stores after it hit number one and saw huge usage. One phone reached a price of $99,900 on eBay before the auction company <a href="https://www.latimes.com/business/technology/la-fi-tn-ebay-99900-iphone-flappy-bird-20140210-story.html">took </a>the listing down.
Read Also: <a href="https://www.benzinga.com/government/24/03/37710878/congress-moves-to-ban-tiktok-could-members-benefit-from-positions-in-social-media-stocks-like-meta-p">Congress Moves To Ban TikTok: Could Members Benefit From Positions In Social Media Stocks Like Meta Platforms?</a>
What Happens Next: There are several <a href="https://www.benzinga.com/general/entertainment/25/01/42834240/kevin-oleary-joins-the-peoples-bid-for-tiktok-as-pending-ban-looms">interested parties in buying</a> the U.S. division of TikTok. A final Supreme Court ruling could see ByteDance cave to the pressure and sell off the U.S. division, which would negate the pending ban.
With the ban set for Jan. 19 and President-elect Donald Trump taking office on Jan. 20, there is also the potential that the incoming president works on some type of deal to please everyone and keep TikTok up and running.
Previously supportive of banning TikTok, Trump has now flipped and is supportive of keeping the platform running. The flip <a href="https://www.benzinga.com/24/12/42654769/tiktok-ban-under-trump-president-elect-wants-to-keep-months-after-pelosi-said-follow-the-money">could be related</a> to a key ByteDance investor being a Trump donor and ally.
Who Benefits From Ban: A ban of TikTok could hurt content creators who have been using the platform for years and turned it into a source of income.
Some content creators have already started producing more content on other platforms, encouraging their TikTok followers to connect with them elsewhere in preparation for a potential ban.
One of the biggest winners from a TikTok ban could be Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), the owner of Facebook and Instagram.
Meta has worked on launching short video content similar to TikTok through Instagram Reels.
Another potential winner could be YouTube, the video platform owned by Alphabet Inc.
YouTube Shorts, which are short video clips, have grown in popularity and could be an easy transition for TikTok creators to move over to.
Other<a href="https://www.benzinga.com/24/12/42512436/tiktok-ban-could-lead-to-more-time-spent-on-youtube-reddit-snapchat"> potential winners</a> could be Snap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) and Reddit Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>).
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42931704/tiktok-users-call-on-trump-to-deliver-immediately-on-his-promise-to-save-app-from-us-ban-we-dont-need-the-supreme-court-to">TikTok Users Call On Trump To &#8216;Deliver Immediately&#8217; On His &#8216;Promise&#8217; To Save App From US Ban: &#8216;We Don&#8217;t Need The Supreme Court To…&#8217;</a></li>
</ul>
Photo: Shutterstock

Social Media

Tech

AAPL

EBAY

GOOG

GOOGL

RDDT

SNAP

TikTok Ban Deadline Ahead: What Will Happen To App On Your Phone?

JP Morgan analyst Joseph Cardoso maintains TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) with a Neutral and raises the price target from $135 to $150.

JP Morgan Maintains Neutral on TD Synnex, Raises Price Target to $150

Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) that it does not already owned by Biogen <a href="https://www.benzinga.com/25/01/42946734/why-is-depression-focused-sage-therapeutics-stock-surging-higher-on-monday" target="_blank" rel="noreferrer noopener">for $7.22 per share</a>.
Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD).
Biogen says Zurzuvae exceeded its expectations.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42397286/biogen-downgraded-on-pipeline-setbacks-and-leqembi-sales-slowdown" rel="noreferrer noopener">Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown</a>
Goldman Sachs estimates Zurzuvae could reach global peak sales of approximately $700 million for PPD by 2034.
Richter notes that investors remain focused on Biogen&#8217;s growth strategies. This includes expanding its pipeline, pursuing external business development, or leveraging new opportunities to counter declining revenue in the latter <a href="https://www.benzinga.com/quote/BIIB/analyst-ratings" target="_blank" rel="noreferrer noopener">half of the decade</a>.
During the third quarter earnings call, management highlighted the potential for an $8 billion to $10 billion deal within the next two years, primarily focusing on rare diseases and immunology.
They also emphasized continued interest in neurology while acknowledging the strength of Biogen&#8217;s immunology capabilities from its multiple sclerosis franchise and the need to diversify further.
William Blair has consistently seen Zurzuvae&#8217;s role in treating postpartum depression as less significant to Biogen&#8217;s overall value. Instead, the firm prioritizes the progress of Biogen&#8217;s late-stage programs and improvements in Leqembi&#8217;s treatment profile.
Analyst Myles Minter suggests that while the deal may not boost Biogen&#8217;s stock, it provides a smart strategy for marketing Zurzuvae and maximizing its value.
If the deal is finalized, Biogen should consider acquiring more companies in the neuropsychiatry field to strengthen its collaboration with Zurzuvae, Minter says.
Price Action: Biogen stock is up 0.34% at $150.32 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42955324/cancer-focused-phio-pharmaceuticals-stock-gains-300-on-monday-heres-why" target="_blank" rel="noreferrer noopener">Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday &#8211; Here&#8217;s Why</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

General

BIIB

SAGE

Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts

Macquarie analyst Tim Nollen maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and raises the price target from $795 to $965.

NFLX

Macquarie Maintains Outperform on Netflix, Raises Price Target to $965

Lake Street analyst Brooks O'Neil maintains ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) with a Buy and lowers the price target from $30 to $10.

MODV

Lake Street Maintains Buy on ModivCare, Lowers Price Target to $10

In the preceding three months, 14 analysts have released ratings for BKV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKV#NYSE">BKV</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $26.43, a high estimate of $33.00, and a low estimate of $23.00. Witnessing a positive shift, the current average has risen by 5.72% from the previous average price target of $25.00.
<img src="https://www.benzinga.com/files/images/story/2025/1736794859_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of BKV by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Bertrand Donnes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Bertrand Donnes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Bertrand Donnes</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Announces</td>
<td>Positive</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Outperform</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$23.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to BKV. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of BKV compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for BKV's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into BKV's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BKV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on BKV analyst ratings.</a>
<h2>Get to Know BKV Better</h2>
BKV Corp is a growth-driven energy company. Its core business is to produce natural gas from its owned and operated upstream businesses. It operates in four business lines: natural gas production, natural gas gathering, processing and transportation (natural gas midstream business), power generation and carbon capture, utilization, and sequestration (CCUS).
<h3>Breaking Down BKV's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: BKV's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -24.33%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: BKV's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 9.34%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): BKV's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.88%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): BKV's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.57%, the company may face hurdles in achieving optimal financial returns.
Debt Management: BKV's debt-to-equity ratio is below the industry average at 0.12, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where BKV Stands With Analysts

President Joe Biden's remaining days in office are dwindling, but one last-minute decision of his could have a major impact on the energy market that will linger long past January 20, 2025.
On January 6, the Biden administration banned offshore drilling in more than 625 million acres of US coastal areas, wetlands, and marine ecosystems. The drilling ban protects those areas from future oil and natural gas leases.
Here&#8217;s how this will affect energy stocks now and in the future.
"Using his authority under Section 12(a) of the Outer Continental Shelf Lands Act, President Biden is issuing two Presidential Memoranda to protect all U.S. Outer Continental Shelf areas off the East and West coasts, the eastern Gulf of Mexico, and additional portions of the Northern Bering Sea in Alaska from future oil and natural gas leasing," the White House said in a statement. "The withdrawals have no expiration date and prohibit all future oil and natural gas leasing in the areas withdrawn."
The S&amp;P Energy Index remained relatively stable the week after the drilling ban was announced, holding in the 665-to-675 range. Yet there may be limited collateral damage to select energy companies from the ban.
Oil and gas companies that rely on offshore drilling, particularly in restricted areas, may see reduced exploration and production opportunities, leading to potential revenue declines," said Mike Blankenship, a capital markets attorney with Winston &amp; Strawn LLP in Houston, Tex. "We will likely continue to see more drilling in the Gulf of Mexico, where regulatory hurdles might be less restrictive. The ban could also contribute to tighter domestic oil and gas supplies in the long term, potentially driving up prices if demand remains steady or increases."
Other energy experts say fears of a significant decline in sector share prices were overblown.
&#8220;President Biden's ban on oil drilling covers approximately 2.54 million square kilometers of oceanic territory, including parts of the Atlantic and Pacific coasts, sections of Alaska's northern Bering Sea, and the eastern Gulf of Mexico," said Igor Isaev, head of the analytics center at the European broker Mind Money. "To put this into perspective, the area is comparable to the size of Sudan or Algeria, which rank 10th and 11th in global landmass, while the U.S. totals 9.37 million square kilometers."
That said, the drilling ban doesn't affect the central and western Gulf of Mexico, which account for about 14.5% of U.S. oil production and 4% of its natural gas output, Isaev noted. "Another thing is that the newly restricted zones contain little in terms of proven reserves," he added. "While the eastern Gulf contains some forecasted but unexplored reserves, their economic viability remains questionable given the rise of onshore shale extraction."
Additionally, the oil and gas markets remain oversupplied through the development of existing oil and gas fields.
"The natural gas market has shown little reaction to the presidential elections, instead being influenced by short-term drivers like weather, storms, and LNG export demand in Europe and Asia playing a greater role," Isaev said. "We expect gas prices to rise in the near term."
Over the long term, the U.S. has the capacity to produce up to 14.5 million barrels of oil daily with its existing infrastructure. "Pushing production beyond this threshold would require significant investment in pipelines and drilling facilities," Isaev said. "Increased oil output would also contribute to associated gas production, and we are already seeing expansion in dedicated gas fields like Marcellus."
The U.S. will likely maintain stable oil and gas prices tied to the Fed's policy, global liquidity, and energy costs.
"The country's main goal lies in affordable, stable energy, which is why it will keep the oil prices in the range of $70–$80 per barrel, which is beneficial for the U.S., and there isn't much reason to lower prices further," Isaev noted. "While President Trump has promised to overturn the ban, history shows such actions face legal hurdles. For example, Trump's 2019 attempt to lift a similar Arctic ban was blocked, and in 2020, Trump himself extended a moratorium on offshore drilling during his presidency."
"Ultimately, the ban itself is unlikely to affect the oil market significantly," he added.
With legal hurdles in place and potential Congressional action needed, what options does the Trump administration have to overturn the drilling ban?
"If the ban includes elements tied to Congressional authority (e.g., restrictions codified in law), overturning it may require bipartisan approval," Blankenship said&nbsp; "This would be difficult if the political makeup of Congress is divided. The Trump administration could attempt to defund enforcement mechanisms tied to the ban, but this strategy would face its own political challenges."
Three Energy Stocks That Should Keep Percolating
With energy stocks experiencing no significant impact from the Biden offshore drilling ban (so far), the outperforming sector stocks should keep rolling &#8211; especially these three energy plays.
Texas Pacific Land Corp. (TPL). This energy stock is pricey at $1,293 per share, but it's been a robust performer lately. The stock is up 153.7% over the past year and the company owns 900,000 acres in the oil-rich Permian Basin.
The company makes big profits on oil and gas royalties and surface leases. Couple that with a debt-free balance sheet, a decent 0.49% dividend yield, and the bullish tone on oil and gas coming from the incoming Trump administration, and TPL should keep its winning streak going in 2025.
Targa Resources (TRGP). Targa, a Houston, Tex.-based midstream natural gas and natural gas liquids services provider, is also on a roll. TRGP's stock price is up 130% over the past year. The company is in full expansion mode, building six natural gas processing centers and a new NGL export terminal, which should be up and running next year.
Scotiabank recently issued an "outperform" call on Targa, with a $218 price target. The stock is currently trading at $195 per share.
Kinder Morgan (KMI). Analysts are also bullish on Houston-based Kinder Morgan, an oil and natural gas pipeline transportation services provider. KMI's share price has been up 58.5% over the past year, and it's expected to post year-over-year earnings increases when it releases earnings numbers from the last quarter of 2024. Overall, analysts expect earnings to rise by 19.9% year-to-year, and revenues are pegged to increase by 1.3% over the same period.
<a href="https://benzinga.zoom.us/webinar/register/WN_OJ2FBspHSJSSVNlW8zGapw/?utm_source=WebRD-0113&amp;el=ResearchDaily">Unlock Momentum &amp; Maximize Profits This Earnings Season</a> Join Ryan Faloona and Anne-Marie Baiynd on Tuesday, January 14, at 6 PM ET for an exclusive webinar. Discover strategies to master earnings season, identify momentum opportunities, and capitalize on fast-moving trends. <a href="https://benzinga.zoom.us/webinar/register/WN_OJ2FBspHSJSSVNlW8zGapw/?utm_source=WebRD-0113&amp;el=ResearchDaily">Reserve your spot now!</a>
Image Via Shutterstock

Opinion

3 Energy Stocks to Buy After Biden's Offshore Oil Ban

In the last three months, 11 analysts have published ratings on Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $64.55, a high estimate of $73.00, and a low estimate of $52.00. Marking an increase of 0.44%, the current average surpasses the previous average price target of $64.27. 
<img src="https://www.benzinga.com/files/images/story/2025/1736794851_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Halozyme Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$53.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$73.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Halozyme Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Halozyme Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Halozyme Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Halozyme Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HALO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Halozyme Therapeutics analyst ratings.</a>
<h2>Delving into Halozyme Therapeutics's Background</h2>
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
<h3>Halozyme Therapeutics's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Halozyme Therapeutics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 34.28%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Halozyme Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 47.23% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Halozyme Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 36.92% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 6.7%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.32, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HALO

Analyst Expectations For Halozyme Therapeutics's Future

In the preceding three months, 5 analysts have released ratings for Magnolia Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.4, a high estimate of $34.00, and a low estimate of $24.00. This upward trend is evident, with the current average reflecting a 0.68% increase from the previous average price target of $29.20.
<img src="https://www.benzinga.com/files/images/story/2025/1736794842_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Magnolia Oil &amp; Gas. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Noah Hungness</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Magnolia Oil &amp; Gas. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Magnolia Oil &amp; Gas compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Magnolia Oil &amp; Gas's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Magnolia Oil &amp; Gas's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MGY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Magnolia Oil &amp; Gas analyst ratings.</a>
<h2>All You Need to Know About Magnolia Oil &amp; Gas</h2>
Magnolia Oil &amp; Gas Corp is an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquid (NGL) reserves. The Company's oil and natural gas properties are located in Karnes County and the Giddings area in South Texas, where the Company targets the Eagle Ford Shale and Austin Chalk formations. Its objective is to generate stock market value over the long term through consistent organic production growth, high full-cycle operating margins, and an efficient capital program with short economic paybacks. The company's operating segment is acquisition, development, exploration, and production of oil and natural gas properties located in the United States.
<h3>Magnolia Oil &amp; Gas: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Magnolia Oil &amp; Gas's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.53% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.
Net Margin: Magnolia Oil &amp; Gas's net margin excels beyond industry benchmarks, reaching 29.59%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Magnolia Oil &amp; Gas's ROE stands out, surpassing industry averages. With an impressive ROE of 5.29%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.49%, the company showcases effective utilization of assets.
Debt Management: Magnolia Oil &amp; Gas's debt-to-equity ratio is below the industry average. With a ratio of 0.21, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Magnolia Oil & Gas: Insights From 5 Analyst Reviews

6 analysts have shared their evaluations of Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $150.33, a high estimate of $166.00, and a low estimate of $125.00. This current average has decreased by 3.12% from the previous average price target of $155.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1736794834_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Xylem. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$147.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$166.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$148.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Joseph Giordano</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$125.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$154.00</td>
<td>$175.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Xylem. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Xylem compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Xylem's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Xylem's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/XYL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Xylem analyst ratings.</a>
<h2>Unveiling the Story Behind Xylem</h2>
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $7.4 billion in revenue in 2023.
<h3>Financial Milestones: Xylem's Journey</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Xylem displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 1.35%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 10.31%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Xylem's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.07%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Xylem's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.36%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Xylem's debt-to-equity ratio is below the industry average at 0.2, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Xylem Stock: Analyst Perspectives (6 Ratings)

AirSculpt Technologies (AIRS) appointed Yogi Jashnani as CEO and a member of the board. He succeeds Dennis Dean, Interim CEO and CFO who will conti...

AirSculpt Technologies appoints Yogi Jashnani as CEO

An announcement from Airsculpt Technologies, Inc. ( ($AIRS) ) is now available. AirSculpt Technologies has announced the appointment of Yogesh Jash...

Airsculpt Technologies Appoints Yogesh Jashnani as CEO

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viatris (VTRS – Research Report) and Airsculpt Tec...

Analysts Offer Insights on Healthcare Companies: Viatris (VTRS) and Airsculpt Technologies, Inc. (AIRS)

Airsculpt Technologies, Inc. ( ($AIRS) ) has provided an update. Airsculpt Technologies, Inc. has announced amendments to the employment agreement ...

Airsculpt Technologies Updates Executive Compensation and Leadership

Piper Sandler lowered the firm's price target on AirSculpt Technologies (AIRS) to $6 from $7 and keeps a Neutral rating on the shares. Heading into...

AirSculpt Technologies price target lowered to $6 from $7 at Piper Sandler

In a report released today, Korinne Wolfmeyer from Piper Sandler maintained a Hold rating on Airsculpt Technologies, Inc. (AIRS – Research Report),...

Piper Sandler Sticks to Their Hold Rating for Airsculpt Technologies, Inc. (AIRS)

FY24 consensus $185.75M. Cuts FY24 adjusted EBITDA view to $20.5M from $23M-$28M. "Last week marked my official start as CEO of AirSculpt and I am ...

AirSculpt Technologies cuts FY24 revenue view to $180M from $183M-$189M

09:41 EST Airsculpt Technologies (AIRS) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking f...

Airsculpt Technologies Inc trading resumes

09:31 EST Airsculpt Technologies (AIRS) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time,...

Airsculpt Technologies Inc trading halted, volatility trading pause

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Johnson & Johnson (JNJ) agreed to acqu...

J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz

AIRS

ATEC

CRZBY

CWAN

ENFN

ESTA

ICHR

INTC

MCHP

MRVL

OPCH

QCOM

RZLV

VTRS

Press Releases

AirSculpt Technologies, Inc. (AIRS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Legal

AirSculpt® Technologies, Inc. Adds New Center In Deerfield, IL To Meet Chicago Market Demand

AirSculpt® Technologies, Inc. Announces Opening of Its New Center in Birmingham, MI

AirSculpt Technologies Announces Preliminary Third Quarter 2024 Revenue Results

AirSculpt Technologies Reports Third Quarter Fiscal 2024 Results

AirSculpt® Technologies, Inc. Announces Opening of Its New White Plains, NY Center

Management

AirSculpt Technologies Names Yogi Jashnani Chief Executive Officer

AirSculpt Technologies Announces Participation in the ICR Conference 2025

AirSculpt Technologies Updates Fiscal Year 2024 Guidance in Advance of its Participation in the ICR Conference 2025

Accolade

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

Castle Biosciences

DocGo

Enhabit

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Fulgent Genetics

InnovAge Holding

23andMe Holding

ModivCare

National Research Corporation - Common Stock

National Research

Nutex Health

Performant Healthcare, Inc. - Common Stock

Performant Healthcare

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Pennant Gr

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

SBC Medical Group Holdings Incorporated - Common Stock

SBC Medical Group Holding

SHL Telemedicine Ltd - American Depositary Shares

Comments

AirSculpt Technologies

Noticias

Últimas noticias sobre AirSculpt Technologies (NASDAQ:AIRS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL